Rheumatoid arthritis and anti-thyroid antibodies

Yavaşoğlu, İrfan; Şentürk, Taşkın; Çoşkun, Adil

doi:10.1080/08916930802428114

Cited by 18 publications

(11 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is widely accepted that among these thyroid antibodies the most frequent is TPOAb compared to TgAb [6]. This has happened in almost all the studies that reported data on both antibodies [57, 70, 77, 80, 82, 87], and in our cohort. Nonetheless, this is not the case in the article from Japan by Nakamura et al [79] in which they found the same prevalence for both antibodies.…”

Section: Discussionsupporting

confidence: 63%

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

et al. 2012

View full text Add to dashboard Cite

Objective. To determine the prevalence and impact of autoimmune thyroid disease (AITD) in patients with rheumatoid arthritis (RA). Methods. Eight-hundred patients were included. The association between AITD and RA was analyzed was analyzed by bivariate and multivariate analysis. In addition, a literature review was done focusing on geographical variations. Results. In our cohort the prevalence of AITD was 9.8% while the presence of antibodies was 37.8% for antithyroperoxidase enzyme (TPOAb) and 20.8% for antithyroglobulin protein (TgAb). The presence of type 2 diabetes, thrombosis, abnormal body mass index, and a high educational level was positively associated with AITD. The literature review disclosed a geographical variation of AITD in RA ranging from 0.5% to 27%. Autoantibody prevalence ranges from 6% to 31% for TgAb, 5% to 37% for TPOAb, and from 11.4% to 32% for the presence of either of the two. Conclusion. AITD is not uncommon in RA and should be systematically assessed since it is a risk factor for developing diabetes and cardiovascular disease. These results may help to further study the common mechanisms of autoimmune diseases, to improve patients' outcome, and to define public health policies. An international consensus to accurately diagnose AITD is warranted.

show abstract

Section: Discussionsupporting

confidence: 63%

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Antithyroid antibodies are common in populations without overt thyroid disease, associated with or induced by concomitant autoimmune disease (i.e., type 1 diabetes mellitus, RA, and Celiac disease; refs. [11][12][13][14][15][16][17], mutations in CTLA-4 (18,19), upregulation of MHC class II molecules on thyrocytes leading to thyroid antigen presentation to autoreactive cells (20), or as we show here, ipilimumab treatment. Our data also confirm previous studies reporting that patients rarely develop RA autoantibodies (21)(22)(23)(24) or autoimmune hepatitis antibodies even in the presence of the related irAE (25)(26)(27)(28).…”

Section: Discussionsupporting

confidence: 53%

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Moel

Rozeman

Kapiteijn

et al. 2019

Cancer Immunology Research

128

View full text Add to dashboard Cite

Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting in autoantibody formation, which could be associated with immune-related adverse events (irAEs) and antitumor efficacy. Twenty-three common clinical autoantibodies in pre-and posttreatment sera from 133 ipilimumab-treated melanoma patients were determined, and their development linked to the occurrence of irAEs, best overall response, and survival. Autoantibodies developed in 19.2% (19/99) of patients who were autoantibody-negative pretreatment. A nonsignificant association was observed between development of any autoantibodies and any irAEs [OR, 2.92; 95% confidence interval (CI) 0.85-10.01]. Patients with antithyroid antibodies after ipilimumab had significantly more thyroid dysfunction under subsequent anti-PD-1 therapy: 7/11 (54.6%) patients with antithyroid antibodies after ipilimumab developed thyroid dysfunction under anti-PD1 versus 7/49 (14.3%) patients without antibodies (OR, 9.96; 95% CI, 1.94-51.1). Patients who developed autoantibodies showed a trend for better survival (HR for all-cause death: 0.66; 95% CI, 0.34-1.26) and therapy response (OR, 2.64; 95% CI, 0.85-8.16). We conclude that autoantibodies develop under ipilimumab treatment and could be a potential marker of ICI toxicity and efficacy.

show abstract

“…In the current study, higher incidences of TPOAbs and TgAbs were found in RA patients compared with the reportedly healthy controls, and a similar result was found in women, which was in accordance with most previous studies. Although no correlation between RF titer and TAbs positivity was observed ( Yavasoglu et al, 2009 ), our results indicated a significantly higher prevalence of both TPOAbs and TgAbs in RA patients with seropositive RF than in those without seropositive RF, which further strengthens the hypothesis of an association between positive TAbs and RA. However, this result deserves further consideration because several cases have been reported showing false-positive results in Tg assays due to interference by RF resulting from its heterophile ability to bind to other Fc-region IgG antibodies ( Massart, Corcuff & Bordenave, 2008 ; Astarita et al, 2015 ).…”

Section: Discussionsupporting

confidence: 73%

Joint damage is amplified in rheumatoid arthritis patients with positive thyroid autoantibodies

Chen

Lin

et al. 2018

PeerJ

View full text Add to dashboard Cite

BackgroundAutoimmune thyroid disease (AITD), which is characterized by an increased presence of thyroid autoantibodies (TAbs), such as antibodies against thyroid peroxidase (TPOAbs) and antibodies against thyroglobulin (TgAbs), has been reported to be associated with rheumatoid arthritis (RA) because AITD and RA both involve autoimmunity. However, few data are available on the incidence of TAbs in Chinese RA patients, and studies on the association between TAbs and joint damage as well as synovitis in RA patients remain sparse. Here, we aimed to evaluate the incidence of TAbs in a consecutive Chinese RA cohort and to investigate whether the elevated presence of TAbs is associated with joint damage and synovitis in RA patients.MethodsA total of 125 hospitalized RA patients were consecutively recruited. Clinical data and available synovial tissues were collected at baseline, and TAbs and thyroid function were detected by chemiluminescent immunoassay. Patients who tested positive for TPOAbs or TgAbs were classified as the TAbs-positive group, and patients who tested positive for neither TPOAbs nor TgAbs were recruited as the TAbs-negative group. Disease activity was assessed using DAS28-ESR (the disease activity score in 28 joints and including the erythrocyte sedimentation rate). X-ray assessment of the hand/wrist was performed according to the Sharp/van der Heijde-modified Sharp score (mTSS), and patients with an mTSS score >10 were defined as having radiographic joint damage (RJD). Serial tissue sections were stained immunohistochemically for CD3, CD15, CD20, CD34, CD38, and CD68, and synovitis were assessed according to Krenn’s synovitis score.ResultsA total of 44 (35%) patients were positive for either TPOAbs or TgAbs. Importantly, there was a significantly greater percentage of patients with RJD in the TAbs-positive group versus the TAbs-negative group (68% vs. 42%, p = 0.005). Compared with the TAbs-negative group, significantly more CD38-positive plasma cells infiltrated the TAbs-positive synovium, and a higher percentage of patients with high-grade synovitis were observed in the TAbs-positive group (5/8, 63% vs. 5/14, 36%). Moreover, RF positivity and disease activity indicators, including TJC28, DAS28-ESR, and CDAI, were significantly higher in the TAbs-positive group (all p < 0.05). Adjusted logistic regression analysis revealed that positive TAbs (OR 2.999, 95% CI [1.301–6.913]; p = 0.010) and disease duration (OR 1.013, 95% CI [1.006–1.019]; p < 0.001) were independently associated with RJD, and an odds ratio of 2.845 (95% CI [1.062–7.622]) was found for RJD in women with positive TAbs (n = 37) compared with those without TAbs (n = 59) (p = 0.038).ConclusionOur data showed that joint destruction was amplified in RA patients with an elevated presence of TAbs, which supports the importance and necessity of TAbs and thyroid function screening and monitoring in RA patient management in clinical practice.

show abstract

Rheumatoid arthritis and anti-thyroid antibodies

Cited by 18 publications

References 2 publications

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Joint damage is amplified in rheumatoid arthritis patients with positive thyroid autoantibodies

Contact Info

Product

Resources

About